AMGEN Inc (AMGN) concluded trading on Thursday at a closing price of $281.41, with 4.68 million shares of worth about $1.32 billion changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -11.42% during that period and on April 10, 2025 the price saw a loss of about -3.33%. Currently the company’s common shares owned by public are about 536.90M shares, out of which, 535.99M shares are available for trading.
Stock saw a price change of -9.18% in past 5 days and over the past one month there was a price change of -9.95%. Year-to-date (YTD), AMGN shares are showing a performance of 7.97% which increased to 4.09% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $253.30 but also hit the highest price of $346.85 during that period. The average intraday trading volume for AMGEN Inc shares is 3.25 million. The stock is currently trading -7.84% below its 20-day simple moving average (SMA20), while that difference is down -7.52% for SMA50 and it goes to -8.12% lower than SMA200.
AMGEN Inc (NASDAQ: AMGN) currently have 536.90M outstanding shares and institutions hold larger chunk of about 79.26% of that.
The stock has a current market capitalization of $151.17B and its 3Y-monthly beta is at 0.50. PE ratio of stock for trailing 12 months is 37.29, while it has posted earnings per share of $7.55 in the same period. Its PEG reads 8.84 and has Quick Ratio of 0.95 while making debt-to-equity ratio of 10.36. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AMGN, volatility over the week remained 6.72% while standing at 3.04% over the month.
Stock’s fiscal year EPS is expected to rise by 4.29% while it is estimated to increase by 4.47% in next year. EPS is likely to grow at an annualized rate of 4.22% for next 5-years, compared to annual growth of -10.10% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on December 10, 2024 offering an Underperform rating for the stock and assigned a target price of $256 to it. On November 14, 2024, Citigroup Initiated their recommendations, while on October 17, 2024, Bernstein Initiated their ratings for the stock with a price target of $380. Stock get a Hold rating from Truist on October 14, 2024.
